Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
2.
Pak J Pharm Sci ; 34(1): 185-196, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34248019

RESUMEN

The role of nanobiotechnology in the treatment of diseases is limitless. In this review we tried to focus main aspects of nanotechnology in drug carrier systems for treatment and diagnosis of various diseases such as cancer, pulmonary diseases, infectious diseases, vaccine development, diabetes mellitus and the role of nanotechnology on our economy and its positive social impacts on our community. We discussed here about the different "Biotechnano Strategies" to develop new avenues and ultimately improve the treatment of multiple diseases.


Asunto(s)
Biotecnología/tendencias , Portadores de Fármacos/administración & dosificación , Nanotecnología/tendencias , Desarrollo de Vacunas/tendencias , Animales , Biotecnología/economía , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/economía , Portadores de Fármacos/economía , Humanos , Nanotecnología/economía , Neoplasias/tratamiento farmacológico , Neoplasias/economía , Desarrollo de Vacunas/economía
4.
ACS Appl Bio Mater ; 4(5): 3880-3890, 2021 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-35006813

RESUMEN

Infectious diseases are a worldwide concern. They are responsible for increasing the mortality rate and causing economic and social problems. Viral epidemics and pandemics, such as the COVID-19 pandemic, force the scientific community to consider molecules with antiviral activity. A number of viral infections still do not have a vaccine or efficient treatment and it is imperative to search for vaccines to control these infections. In this context, nanotechnology in association with the design of vaccines has presented an option for virus control. Nanovaccines have displayed an impressive immune response using a low dosage. This review aims to describe the advances and update the data in studies using nanovaccines and their immunomodulatory effect against human viruses.


Asunto(s)
Nanomedicina/tendencias , Desarrollo de Vacunas/tendencias , Vacunas Virales , Virosis/prevención & control , Inmunidad Adaptativa , Vacunas contra la COVID-19 , Humanos , Inmunidad Innata , Vacunas de ADN , Vacunas de Subunidad , Vacunas Sintéticas , Vacunas Virales/inmunología , Vacunas de ARNm
5.
Mil Med Res ; 8(1): 67, 2021 12 16.
Artículo en Inglés | MEDLINE | ID: mdl-34911569

RESUMEN

Since the end of 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The RNA genome of SARS-CoV-2, which is highly infectious and prone to rapid mutation, encodes both structural and nonstructural proteins. Vaccination is currently the only effective method to prevent COVID-19, and structural proteins are critical targets for vaccine development. Currently, many vaccines are in clinical trials or are already on the market. This review highlights ongoing advances in the design of prophylactic or therapeutic vaccines against COVID-19, including viral vector vaccines, DNA vaccines, RNA vaccines, live-attenuated vaccines, inactivated virus vaccines, recombinant protein vaccines and bionic nanoparticle vaccines. In addition to traditional inactivated virus vaccines, some novel vaccines based on viral vectors, nanoscience and synthetic biology also play important roles in combating COVID-19. However, many challenges persist in ongoing clinical trials.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19/prevención & control , Desarrollo de Vacunas , Humanos , SARS-CoV-2 , Desarrollo de Vacunas/tendencias , Vacunas de ARNm
6.
Arch Immunol Ther Exp (Warsz) ; 69(1): 12, 2021 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-33909124

RESUMEN

In this communication, we will analyze some important factors and immunological phenomena related to neoantigen cancer vaccines, with particular emphasis on recently published Phase I clinical trials. Several obstacles and issues are addressed that challenge the current paradigm and inquire if neoantigens, which are essentially single-use vaccine candidates, are legitimate targets to induce protective immune responses with regard to the evolving mutational landscape. We also share insights into the striking similarities between cancer and antigenically variable pathogens and suggest that any successful vaccine against either should demonstrate a similar property: efficient induction of a diverse pool of immune cells equipped to prevent immune escape. Hence, to confront antigenic variability directly, we have employed our innovative vaccine concept, Variable Epitope Libraries, composed of large combinatorial libraries of heavily mutated epitopes, as a "universal" vaccine platform. Collectively, we offer critical analyses on key issues, which ultimately reflect on the prospective clinical relevance of personalized neoantigen vaccines which is still undefined.


Asunto(s)
Antígenos de Neoplasias/uso terapéutico , Vacunas contra el Cáncer/uso terapéutico , Neoplasias/terapia , Desarrollo de Vacunas/métodos , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/inmunología , Vacunas contra el Cáncer/genética , Vacunas contra el Cáncer/inmunología , Ensayos Clínicos Fase I como Asunto , Epítopos/genética , Epítopos/inmunología , Humanos , Inmunogenicidad Vacunal , Mutación , Neoplasias/genética , Neoplasias/inmunología , Resultado del Tratamiento , Escape del Tumor/genética , Desarrollo de Vacunas/tendencias
7.
Front Immunol ; 12: 711997, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34326849

RESUMEN

Influenza A virus is one of the most important zoonotic pathogens that can cause severe symptoms and has the potential to cause high number of deaths and great economic loss. Vaccination is still the best option to prevent influenza virus infection. Different types of influenza vaccines, including live attenuated virus vaccines, inactivated whole virus vaccines, virosome vaccines, split-virion vaccines and subunit vaccines have been developed. However, they have several limitations, such as the relatively high manufacturing cost and long production time, moderate efficacy of some of the vaccines in certain populations, and lack of cross-reactivity. These are some of the problems that need to be solved. Here, we summarized recent advances in the development and application of different types of influenza vaccines, including the recent development of viral vectored influenza vaccines. We also described the construction of other vaccines that are based on recombinant influenza viruses as viral vectors. Information provided in this review article might lead to the development of safe and highly effective novel influenza vaccines.


Asunto(s)
Vacunas contra la Influenza , Desarrollo de Vacunas , Animales , Pollos , Predicción , Vectores Genéticos , Humanos , Virus de la Influenza A/genética , Virus de la Influenza A/inmunología , Gripe Aviar/prevención & control , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Gripe Humana/virología , Enfermedades de las Aves de Corral/prevención & control , Estaciones del Año , Desarrollo de Vacunas/tendencias , Vacunas Atenuadas , Vacunas de Productos Inactivados , Vacunas de Subunidad , Vacunas Sintéticas , Vacunas de Virosoma , Virión
8.
Front Immunol ; 12: 711650, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34489961

RESUMEN

Helminths contribute a larger global burden of disease than both malaria and tuberculosis. These eukaryotes have caused human infections since before our earliest recorded history (i.e.: earlier than 1200 B.C. for Schistosoma spp.). Despite the prevalence and importance of these infections, helminths are considered a neglected tropical disease for which there are no vaccines approved for human use. Similar to other parasites, helminths are complex organisms which employ a plethora of features such as: complex life cycles, chronic infections, and antigenic mimicry to name a few, making them difficult to target by conventional vaccine strategies. With novel vaccine strategies such as viral vectors and genetic elements, numerous constructs are being defined for a wide range of helminth parasites; however, it has yet to be discussed which of these approaches may be the most effective. With human trials being conducted, and a pipeline of potential anti-helminthic antigens, greater understanding of helminth vaccine-induced immunity is necessary for the development of potent vaccine platforms and their optimal design. This review outlines the conventional and the most promising approaches in clinical and preclinical helminth vaccinology.


Asunto(s)
Helmintiasis/prevención & control , Helmintos/inmunología , Invenciones , Desarrollo de Vacunas/tendencias , Vacunas , Adyuvantes Inmunológicos , Animales , Antígenos Helmínticos/inmunología , Ensayos Clínicos como Asunto , Helmintiasis/epidemiología , Helmintiasis/inmunología , Helmintos/efectos de la radiación , Humanos , Inmunogenicidad Vacunal , Ratones , Vacunación Basada en Ácidos Nucleicos , Células Th2/inmunología , Vacunación , Eficacia de las Vacunas , Vacunas/inmunología , Vacunas Atenuadas , Vacunas de Subunidad , Vacunas Sintéticas
9.
Viruses ; 13(8)2021 08 12.
Artículo en Inglés | MEDLINE | ID: mdl-34452460

RESUMEN

Unless urgently needed to prevent a pandemic, the development of a viral vaccine should follow a rigorous scientific approach. Each vaccine candidate should be designed considering the in-depth knowledge of protective immunity, followed by preclinical studies to assess immunogenicity and safety, and lastly, the evaluation of selected vaccines in human clinical trials. The recently concluded first phase II clinical trial of a human hepatitis C virus (HCV) vaccine followed this approach. Still, despite promising preclinical results, it failed to protect against chronic infection, raising grave concerns about our understanding of protective immunity. This setback, combined with the lack of HCV animal models and availability of new highly effective antivirals, has fueled ongoing discussions of using a controlled human infection model (CHIM) to test new HCV vaccine candidates. Before taking on such an approach, however, we must carefully weigh all the ethical and health consequences of human infection in the absence of a complete understanding of HCV immunity and pathogenesis. We know that there are significant gaps in our knowledge of adaptive immunity necessary to prevent chronic HCV infection. This review discusses our current understanding of HCV immunity and the critical gaps that should be filled before embarking upon new HCV vaccine trials. We discuss the importance of T cells, neutralizing antibodies, and HCV genetic diversity. We address if and how the animal HCV-like viruses can be used for conceptualizing effective HCV vaccines and what we have learned so far from these HCV surrogates. Finally, we propose a logical but narrow path forward for HCV vaccine development.


Asunto(s)
Hepacivirus/inmunología , Hepatitis C/inmunología , Hepatitis C/prevención & control , Desarrollo de Vacunas/estadística & datos numéricos , Vacunas contra Hepatitis Viral/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Antivirales/uso terapéutico , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Hepatitis C/tratamiento farmacológico , Anticuerpos contra la Hepatitis C/inmunología , Antígenos de la Hepatitis C/inmunología , Hepatitis C Crónica/inmunología , Hepatitis C Crónica/prevención & control , Humanos , Infección Persistente , Desarrollo de Vacunas/métodos , Desarrollo de Vacunas/normas , Desarrollo de Vacunas/tendencias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA